Robert Sherrill is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he advises public and private companies on the tax aspects related to domestic and cross-border transactions. He handles a broad range of tax issues, including mergers and acquisitions, joint ventures, restructurings, equity offerings, investment funds, and debt financings.
Experience
Robert Sherrill is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he advises public and private companies on the tax aspects related to domestic and cross-border transactions. He handles a broad range of tax issues, including mergers and acquisitions, joint ventures, restructurings, equity offerings, investment funds, and debt financings.
Education
- J.D., University of Southern California, Gould School of Law, 2024
- B.A., University of North Carolina at Chapel Hill, 2015
Admissions
- State Bar of California
Credentials
Education
- J.D., University of Southern California, Gould School of Law, 2024
- B.A., University of North Carolina at Chapel Hill, 2015
Admissions
- State Bar of California
Select Publications
- Co-author with M. Sutanto Shen, “Eligibility of Life Sciences Companies for Qualified Small Business Stock,” The Life Sciences Report, Wilson Sonsini, January 2025
Insights
Select Publications
- Co-author with M. Sutanto Shen, “Eligibility of Life Sciences Companies for Qualified Small Business Stock,” The Life Sciences Report, Wilson Sonsini, January 2025
Recent Insights
Client Highlights
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Saturnus Bio on Strategic Collaboration with Merck KGaA, Darmstadt, Germany
On June 23, 2026, Merck KGaA, Darmstadt, Germany, a leading global science and technology company, announced a strategic collaboration with Versant Ventures to launch Saturnus Bio, a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Wilson Sonsini Goodrich & Rosati advised Saturnus Bio on the transaction.
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.